The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis

Samuel D. Vasikaran; Paul Chubb

doi:10.1007/s12020-016-0900-2

The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis

Samuel D. Vasikaran, Paul Chubb

Research output: Contribution to journal › Article

15 Citations (Scopus)

Abstract

© 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of

Original language	English
Pages (from-to)	222-225
Number of pages	4
Journal	Endocrine
Volume	52
Issue number	2
DOIs	https://doi.org/10.1007/s12020-016-0900-2
Publication status	Published - 2016

Fingerprint

Cite this

Vasikaran, S. D., & Chubb, P. (2016). The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. Endocrine, 52(2), 222-225. https://doi.org/10.1007/s12020-016-0900-2

@article{a0296321ca524988ae796249c5d6f7e2,

title = "The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis",

abstract = "{\circledC} 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of",

author = "Vasikaran, {Samuel D.} and Paul Chubb",

year = "2016",

doi = "10.1007/s12020-016-0900-2",

language = "English",

volume = "52",

pages = "222--225",

journal = "Endocrine",

issn = "1355-008X",

number = "2",

}

TY - JOUR

T1 - The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis

AU - Vasikaran, Samuel D.

AU - Chubb, Paul

PY - 2016

Y1 - 2016

N2 - © 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of

AB - © 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of

U2 - 10.1007/s12020-016-0900-2

DO - 10.1007/s12020-016-0900-2

M3 - Article

VL - 52

SP - 222

EP - 225

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 2

ER -

Access to Document

10.1007/s12020-016-0900-2